---
figid: PMC6977568__i1947-6094-15-4-250-f01
figtitle: HER2 signaling pathways in cancer cell and cardiac myocyte
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC6977568
filename: i1947-6094-15-4-250-f01.jpg
figlink: pmc/articles/PMC6977568/figure/i1947-6094-15-4-250-f01/
number: F1
caption: 'HER2 signaling pathways in cancer cell and cardiac myocyte. (A) In cancer
  cells, the HER2 signaling pathway is activated via different mechanisms. Trastuzumab
  and lapatinib block HER2 signaling at different levels. (B) In cardiac myocytes,
  HER2 signaling is involved in pro-survival pathways, which can be blocked by HER2-targeted
  therapies. HER2: human epidermal receptor 2; ErbB4: erythroblastic leukemia viral
  oncogene B receptors; NRG-1: neuregulin-1 ligand; TK: tyrosine kinase; MAP-RAS-ERK:
  mitogen-activated protein kinase-rate sarcoma virus oncogene-extracellular signal-regulated
  kinase; PI3K-AKT: phosphatidylinositol 3-kinase-protein kinase B; JAK-STAT: Janus
  kinase-signal transducer and activator of transcription protein; Top-2B: topoisomerase-2
  beta isoform; DOX: doxorubicin; ROS: reactive oxygen species'
papertitle: Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.
reftext: Tolulope A. Agunbiade, et al. Methodist Debakey Cardiovasc J. 2019 Oct-Dec;15(4):250-257.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.652575
figid_alias: PMC6977568__F1
figtype: Figure
redirect_from: /figures/PMC6977568__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6977568__i1947-6094-15-4-250-f01.html
  '@type': Dataset
  description: 'HER2 signaling pathways in cancer cell and cardiac myocyte. (A) In
    cancer cells, the HER2 signaling pathway is activated via different mechanisms.
    Trastuzumab and lapatinib block HER2 signaling at different levels. (B) In cardiac
    myocytes, HER2 signaling is involved in pro-survival pathways, which can be blocked
    by HER2-targeted therapies. HER2: human epidermal receptor 2; ErbB4: erythroblastic
    leukemia viral oncogene B receptors; NRG-1: neuregulin-1 ligand; TK: tyrosine
    kinase; MAP-RAS-ERK: mitogen-activated protein kinase-rate sarcoma virus oncogene-extracellular
    signal-regulated kinase; PI3K-AKT: phosphatidylinositol 3-kinase-protein kinase
    B; JAK-STAT: Janus kinase-signal transducer and activator of transcription protein;
    Top-2B: topoisomerase-2 beta isoform; DOX: doxorubicin; ROS: reactive oxygen species'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - nrg1
  - her2
  - kita
  - ngfra
  - top2b
  - tp53
  - erbb3a
  - per2
  - NRG1
  - ERBB2
  - TK1
  - TK2
  - TOP2B
  - ATP8A2
  - TP53
  - TP63
  - TP73
  - EGFR
  - ERBB3
  - ERBB4
  - PER2
  - Lapatinib
  - DOX
  - ATP
  - cancer
  - Hypertrophy
---
